Choose Your Country or Region

AZD6482

Name: AZD6482
Brand: Selleck Chemicals
SKU: S1462
Rating: 5 (22 reviews)

Catalog No.S1462 Synonyms: KIN-193

For research use only.

AZD6482 (KIN-193) is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ in cell-free assays. Phase 1.

CAS No. 1173900-33-8

Selleck's AZD6482 has been cited by 22 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Related Compound Libraries

Other PI3K Products

Taselisib (GDC 0032)^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.
Pilaralisib (XL147)^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin (KY 12420)

Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.

Download Inhibitor Catalog

PI3K Signaling Pathway Map

Biological Activity

Description

AZD6482 (KIN-193) is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ in cell-free assays. Phase 1.

Targets

PI3Kβ ^[1] (Cell-free assay)	PI3Kδ ^[1] (Cell-free assay)	DNA-PK ^[1] (Cell-free assay)	PI3Kα ^[1] (Cell-free assay)
10 nM	80 nM	420 nM	870 nM

In vitro

AZD6482 also inhibits PI3Kα, γ, and δ, with IC50 of 80 nM to 1.09 μM, which are significantly lower than its (+)-enantiomer (S-form). AZD6482 is an antiplatelet agent; it blocks platelet activation adhesion/aggregation and promotes platelet disaggregation in assay of washed platelet aggregation (WPA), with an IC50 value of 6 nM. Furthermore, by targeting PI3Kβ, AZD6482 specifically inhibits thrombosis without interfering with normal haemostasis. Therefore, AZD6482 is used as an anti-thrombotic drug for the prophylaxis of thrombotic disorders. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

human RXF393 cell	NVPuPGtiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mkn1TY5pcWKrdHnvckBw\iCqdX3hckBTYEZ\|OUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlAyOTV2IN88US=>	MoG5V2FPT0WU
human SW982 cell	NV;rVlJFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M2fRXGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA{PTh2IN88US=>	MkLwV2FPT0WU
human MAD-MB-468 cells	MVHGeY5kfGmxbjDhd5NigQ>?	NF;QVpZKdmirYnn0bY9vKG:oIGDJN2tj\XSjIHnuJIh2dWGwIF3BSE1OSi12NkigZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCVZYK0O\|MhSWu2IIDoc5NxcG:{eXzheIlwdiCkeTDj[YxtfWyjcjDwc5RmdmO7IHHzd4F6NCCLQ{WwQVAvODRizszN	NFLlOHgzPDl7Mki3OC=>
human KURAMOCHI cell	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MkHTTY5pcWKrdHnvckBw\iCqdX3hckBMXVKDTV;DTGkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjFyNUGg{txO	MWLTRW5ITVJ?
human A498 cell	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Ml\TTY5pcWKrdHnvckBw\iCqdX3hckBCPDl6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6xNVc6PSEQvF2=	NHW0U3ZUSU6JRWK=
human YT cell	M1joOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Mn\aTY5pcWKrdHnvckBw\iCqdX3hckB[XCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwMUKwOlYh\|ryP	M{S5OnNCVkeHUh?=
human VMRC-RCZ cell	M2rrdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MW\Jcohq[mm2aX;uJI9nKGi3bXHuJHZOWkNvUlPaJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPDh7ODFOwG0>	Mk\VV2FPT0WU
human MDA-MB-415 cell	NWO0WWo3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXLhdY9ZUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuPDF3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6xOlc{OiEQvF2=	NVfkSVBQW0GQR1XS
human J82 cell	NWq1UXdFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NF3pb5BKdmirYnn0bY9vKG:oIHj1cYFvKEp6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuOFc4PzlizszN	NFjZdHdUSU6JRWK=
human SW1710 cell	M{XyVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NInhUopKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTJ7MjFOwG0>	NEHrdmFUSU6JRWK=
human T47D cell	NX3XTXRkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MoDYTY5pcWKrdHnvckBw\iCqdX3hckBVPDeGIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD61N\|I4KM7:TR?=	Mmf1V2FPT0WU
human SU-DHL-1 cell	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MofUTY5pcWKrdHnvckBw\iCqdX3hckBUXS2GSFytNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTZ6MUOg{txO	MW\TRW5ITVJ?
human BT-20 cell	NEnINVZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2ntcmlvcGmkaYTpc44hd2ZiaIXtZY4hSlRvMkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU6OjJ{IN88US=>	M2X3U3NCVkeHUh?=
human OS-RC-2 cell	M{H1Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MXjJcohq[mm2aX;uJI9nKGi3bXHuJG9UNVKFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlYzOzh6IN88US=>	MlP0V2FPT0WU
human RPMI-6666 cell	Mn\QS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M{T4c2lvcGmkaYTpc44hd2ZiaIXtZY4hWlCPST22OlY3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC54NEO3PUDPxE1?	NX2yWmVWW0GQR1XS
human OVCAR-3 cell	MmfpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NF\BOphKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjZ5OUS2JO69VQ>?	MYrTRW5ITVJ?
human NALM-6 cell	NUf6W2dNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MnfZTY5pcWKrdHnvckBw\iCqdX3hckBPSUyPLU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlcxPDZ3IN88US=>	MorFV2FPT0WU
human RS4-11 cell	NW\uNmY2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXnYTFJ[UW6qaXLpeIlwdiCxZjDoeY1idiCUU{StNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjd\|OEC2JO69VQ>?	Ml3DV2FPT0WU
human SK-MES-1 cell	M1LsZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MXzJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44QDl4NzFOwG0>	M3\CWnNCVkeHUh?=
human ES7 cell	NF3Xc3JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MojoTY5pcWKrdHnvckBw\iCqdX3hckBGWzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkixNlg3KM7:TR?=	NH3mNWNUSU6JRWK=
human NCI-H2342 cell	NXrEb2pOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M4\zdmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyN\|QzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56NEK5OEDPxE1?	NXrjPGZoW0GQR1XS
human SCC-9 cell	NVzsVY92T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M4rtUmlvcGmkaYTpc44hd2ZiaIXtZY4hW0OFLUmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg2PzdizszN	MX3TRW5ITVJ?
human EW-7 cell	NG\zZ\|RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	Mn;5TY5pcWKrdHnvckBw\iCqdX3hckBGXy15IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD64OlM2PiEQvF2=	MmrtV2FPT0WU
human HH cell	MnXyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MlW2TY5pcWKrdHnvckBw\iCqdX3hckBJUCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwOU[yNlIh\|ryP	NEf6blhUSU6JRWK=
human A427 cell	NIm5[WhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NFXEWZpKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk6PTB3IN88US=>	NXXx[WhFW0GQR1XS
human Daudi cell	MnXyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M4LhbWlvcGmkaYTpc44hd2ZiaIXtZY4hTGG3ZHmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA3QDh6IN88US=>	MmjwV2FPT0WU
human P30-OHK cell	NV7ST5JWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NGK1eFJKdmirYnn0bY9vKG:oIHj1cYFvKFB\|MD3PTGsh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjB5MUO4JO69VQ>?	M1v4UHNCVkeHUh?=
human HGC-27 cell	M1jmSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MlzTTY5pcWKrdHnvckBw\iCqdX3hckBJT0NvMkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4Phfg+9lCCLQ{WwQVEvOThzNjFOwG0>	MlfrV2FPT0WU
human CAMA-1 cell	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmjMTY5pcWKrdHnvckBw\iCqdX3hckBESU2DLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlIxODFizszN	MnfMV2FPT0WU
human SK-OV-3 cell	M3jWOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MWDJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU:YLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlIxPDR2IN88US=>	NE[0VmtUSU6JRWK=
human NCI-H1048 cell	MkDJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M4TpfGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNFQ5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{MkW3PUDPxE1?	MVnTRW5ITVJ?
human MEL-HO cell	MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MkTxTY5pcWKrdHnvckBw\iCqdX3hckBOTUxvSF:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlI1OjN6IN88US=>	MXXTRW5ITVJ?
human NKM-1 cell	M1;rR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NEfUXIhKdmirYnn0bY9vKG:oIHj1cYFvKE6NTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zQDZ\|NjFOwG0>	MYHTRW5ITVJ?
human NCI-H650 cel	MmP5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVnMUoZiUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFY2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwM{CwO\|Yh\|ryP	MkLPV2FPT0WU
human HAL-01 cell	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MnnTTY5pcWKrdHnvckBw\iCqdX3hckBJSUxvMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlMxOTd3IN88US=>	NHTuT\|RUSU6JRWK=
human 786-0 cell	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MUjJcohq[mm2aX;uJI9nKGi3bXHuJFc5Pi1yIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6zNVI5OyEQvF2=	MlexV2FPT0WU
human GI-1 cell	M4H3OWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M2DhOGlvcGmkaYTpc44hd2ZiaIXtZY4hT0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuN\|E5ODhizszN	M3LWXXNCVkeHUh?=
human Becker cell	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MULJcohq[mm2aX;uJI9nKGi3bXHuJGJm[2uncjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuN\|Y{OTVizszN	M{DORXNCVkeHUh?=
human CCF-STTG1 cell	NFX0NmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2\SU2lvcGmkaYTpc44hd2ZiaIXtZY4hS0OILWPUWGcyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS52MkWyOUDPxE1?	NGK1OZhUSU6JRWK=
human MC116 cell	M33Zbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NGDBNVZKdmirYnn0bY9vKG:oIHj1cYFvKE2FMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PjF{MjFOwG0>	NVLtUlBwW0GQR1XS
human MDA-MB-468 cell	M4fD[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1zxUWlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVQ3QCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwNUO3N\|Yh\|ryP	NXTGPJVHW0GQR1XS
human NB12 cell	M1jZemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MXHJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkW0PFQzKM7:TR?=	MUXTRW5ITVJ?
human LXF-289 cell	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Ml36TY5pcWKrdHnvckBw\iCqdX3hckBNYEZvMki5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42PTFyNDFOwG0>	MWDTRW5ITVJ?
human MFE-296 cell	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmjxTY5pcWKrdHnvckBw\iCqdX3hckBOTkVvMkm2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42Pjh\|NjFOwG0>	Moj0V2FPT0WU
human SNU-423 cell	NGqyeplIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NFzI[XRKdmirYnn0bY9vKG:oIHj1cYFvKFOQVT20NlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjV5MUmyJO69VQ>?	MmLOV2FPT0WU
human NCI-H2291 cell	NVHRT\|FNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mn70TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKyPVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjV5NkGg{txO	MknwV2FPT0WU
human OCUB-M cell	NVv4cmZwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MWTJcohq[mm2aX;uJI9nKGi3bXHuJG9EXUJvTTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOVg{OTRizszN	Mom5V2FPT0WU
human KU812 cell	NUn2NnlYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M37nN2lvcGmkaYTpc44hd2ZiaIXtZY4hU1V6MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU6PjJ6IN88US=>	M1HPfHNCVkeHUh?=
human HuO9 cell	M{\S[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NVezO4o2UW6qaXLpeIlwdiCxZjDoeY1idiCKdV:5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43OTJ6IN88US=>	M3ntbnNCVkeHUh?=
human 639-V cell	M2[xfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3rtWmlvcGmkaYTpc44hd2ZiaIXtZY4hPjN7LW[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlY{OTR2IN88US=>	NGf0UlRUSU6JRWK=
human HCC70 cell	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGhESzdyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT62OlE1PiEQvF2=	NGTUbFRUSU6JRWK=
human SNB75 cell	M4DRPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Mkn6TY5pcWKrdHnvckBw\iCqdX3hckBUVkJ5NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOlY2ODhizszN	MXnTRW5ITVJ?
human D-336MG cell	MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1rlZWlvcGmkaYTpc44hd2ZiaIXtZY4hTC1\|M{\NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjZ6ODFOwG0>	NYDaUG86W0GQR1XS
human LoVo cell	NUn4dnZLT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NWL1RpRDUW6qaXLpeIlwdiCxZjDoeY1idiCOb2\vJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU44Ozh{NTFOwG0>	MoHDV2FPT0WU
human EB2 cell	M3\veGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3y3[GlvcGmkaYTpc44hd2ZiaIXtZY4hTUJ{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT63OVAyQSEQvF2=	NGTuTYhUSU6JRWK=
human HSC-2 cell	M3\Zd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NIe3XVdKdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU44PTd{NzFOwG0>	NHTyb4dUSU6JRWK=
human D-542MG cell	NH:5T5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NW\FcmNmUW6qaXLpeIlwdiCxZjDoeY1idiCGLUW0Nm1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS56NUC3O{DPxE1?	NVXzbpVPW0GQR1XS
human COLO-684 cell	NHO3cWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2O0PWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22PFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjJyMEOyJO69VQ>?	M4PlNnNCVkeHUh?=
human GDM-1 cell	NGjKOnJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MWPJcohq[mm2aX;uJI9nKGi3bXHuJGdFVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6yOFIxPiEQvF2=	NH7uZnRUSU6JRWK=
human SW1088 cell	NYLqPXBJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NYHyfI1LUW6qaXLpeIlwdiCxZjDoeY1idiCVV{GwPFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjR6MUSzJO69VQ>?	MXfTRW5ITVJ?
human SF295 cell	M{\FSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3\CNGlvcGmkaYTpc44hd2ZiaIXtZY4hW0Z{OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlc3QTV3IN88US=>	NFPhfFRUSU6JRWK=
human NCI-H2030 cell	MnPqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MYLJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkCzNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQTB{OEig{txO	Mlf4V2FPT0WU
human NCI-H1755 cell	MlzWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NHu1OHVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVc2PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTNwMkewOlMh\|ryP	Mom3V2FPT0WU
human MDA-MB-361 cell	MkTHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M1Tod2lvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVM3OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTNwNUK3NFkh\|ryP	MV\TRW5ITVJ?

Click to View More Cell Line Experimental Data

Protocol (from reference)

Kinase Assay:^[1]

Assay of PI3K enzyme inhibition:
The inhibition of PI3Kβ, PI3Kα, PI3Kγ, and PI3Kδ is evaluated in an AlphaScreen based enzyme activity assay using human recombinant enzymes. The assay measures PI3K-mediated conversion of PIP2 to PIP3. Biotinylated PIP3, a GST-tagged pleckstrin homology (PH) domain and the two AlphaScreen beads form a complex that elicits a signal upon laser excitation at 680 nm. The PIP3 formed in the enzyme reaction competes with the biotinylated PIP3 for binding to the PH domain thus reducing the signal with increasing enzyme product. The AZD6482 is dissolved in DMSO and added to 384 well plates. PBKβ, PBKα, PBKγ, or PBKδ is added in a Tris buffer (50 mM Tris pH 7.6, 0.05% CHAPS, 5 mM DTT, and 24 mM MgCl₂) and allowed to preincubate with AZD6482 for 20 minutes prior to the addition of substrate solution containing PIP2 and ATP. The enzyme reaction is stopped after 20 minutes by addition of stop solution containing EDTA and biotin-PIP3, followed by addition of detection solution containing GST-grpl PH and AlphaScreen beads. Plates are left for a minimum of 5 hours in the dark prior to analysis. The final concentration of DMSO, ATP and PIP2 in the assay are, 0.8%, 4 μM, and 40 μM, respectively. IC50 values are calculated according to the equation, y = {a+[(b-a)/(l+(x/IC50)^s)]}, where y = % inhibition; a = 0%; b = 100%; s = the slope of the concentration-response curve; x = AZD6482 concentration.

Cell Research:^[1]

Cell lines: Human platelet pellet
Concentrations: 0–60 nM, dissolved in DMSO
Incubation Time: 5 min
Method: For assay of washed platelet aggregation (WPA), the platelet pellets are isolated from human blood and re-suspended to 2 × 10¹⁵/L in Tyrodes buffer (TB) containing 1 μM hirudin and 0.02 U/mL apyrase. Then, the platelet suspension is left to rest at room temperature for 30 min. Just prior to time for assay, CaCl₂ is added to a final concentration of 2 mM. AZD6482, dissolved in DMSO, is added to a 96-well plate prior to the addition of the washed platelet suspension. The platelet suspension is preincubated with AZD6482 for 5 min. Light absorption at 650 nm is recorded before and after a 5 min plate shake and referred to as recording 0 (R0) and Rl. A mouse anti-human CD9 antibody is added (at a donor specific concentration) to each well prior to next 10 min plate shake and light absorption recording; R2. For data analysis, light absorbance in wells with TB are subtracted from all readings before percent aggregation is calculated according the formula: [(R1-R2)/R1] × 100 = % aggregation. Spontaneous aggregation or pro-aggregatory effect of the inhibitor is evaluated by the same formula, [(R0-Rl)/R0] × 100 = % aggregation. IC50 values are calculated according to the equation, y = {a+[(b-a)/(l+(x/IC50)^s)]}, where y = % inhibition; a = 0%; b = 100%; s = the slope of the concentration-response curve; x = AZD6482 concentration.
(Only for Reference)

References

[1] Fjellstrom O, et al. US Patent, WO2009093972.

Solubility (25°C)

In vitro	DMSO	82 mg/mL (200.75 mM)
	Ethanol	10 mg/mL (24.48 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing. Click to purchase: PEG400 Tween 80	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	408.45
Formula	C₂₂H₂₄N₄O₄
CAS No.	1173900-33-8
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CC1=CN2C(=O)C=C(N=C2C(=C1)C(C)NC3=CC=CC=C3C(=O)O)N4CCOCC4

Download AZD6482 SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):